Analyst Price Target is $13.75
▲ +89.66% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Profound Medical in the last 3 months. The average price target is $13.75, with a high forecast of $16.50 and a low forecast of $12.00. The average price target represents a 89.66% upside from the last price of $7.25.
Current Consensus is
Buy
The current consensus among 4 contributing investment analysts is to buy stock in Profound Medical. This rating has held steady since February 2024, when it changed from a Moderate Buy consensus rating.
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.
Read More